GL0071

GL0071 is an investigational metabolic therapy developed by Sun Pharmaceutical Industries, currently in Phase 1 clinical development for the treatment of type 2 diabetes mellitus, overweight, and obesity. It is a multi-agonist peptide designed to activate the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-agonist approach is intended to leverage the synergistic effects of these pathways on insulin secretion, appetite regulation, and energy expenditure to achieve significant weight loss and glycemic control. The drug is administered via subcutaneous injection and is being evaluated for safety, tolerability, and pharmacokinetics in a first-in-human study (EU CTIS 2025-524233-45-00) conducted in Belgium.